Raptiva and Dermatitis - atopic - a phase IV clinical study of FDA data

Summary:

Dermatitis - atopic is reported as a side effect among people who take Raptiva (efalizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Omeprazole, and have High blood pressure.

The phase IV clinical study analyzes which people have Dermatitis - atopic when taking Raptiva. It is created by eHealthMe based on reports of 3,760 people who have side effects when taking Raptiva from the FDA, and is updated regularly.

What is Raptiva?

Raptiva has active ingredients of efalizumab. It is often used in psoriasis. eHealthMe is studying from 3,769 Raptiva users. Check the latest studies of Raptiva.

What is Dermatitis - atopic?

Dermatitis - atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 2,002 drugs and 1,973 conditions by eHealthMe. Check the latest studies of Dermatitis - atopic.

On Jul, 15, 2026

3,760 people reported to have side effects when taking Raptiva.
Among them, 12 people (0.32%) have Dermatitis - atopic.

Could Raptiva cause Dermatitis - atopic?

Among these 12 people:

How long have people been on Raptiva when they have Dermatitis - atopic? *

What is the gender of people who have Dermatitis - atopic when taking Raptiva? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Dermatitis - atopic when taking Raptiva? *

What are other drugs people take besides Raptiva? *

What are other side effects people have besides Dermatitis - atopic? *

Hepatitis Acute: 4 people, 33.33%
Rashes (redness): 3 people, 25.00%
Drowsiness: 3 people, 25.00%
Renal Impairment (severely reduced kidney function): 2 people, 16.67%
Influenza Like Illness: 2 people, 16.67%
Hair Loss: 2 people, 16.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 16.67%
Toxic Skin Eruption (skin breakdown due to toxic substance): 1 person, 8.33%
Itching: 1 person, 8.33%
Hypersensitivity: 1 person, 8.33%

What are the existing conditions these people have? *

High Blood Pressure: 2 people, 16.67%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 8.33%
Cutaneous Lupus Erythematosus (own immune system attacks various cells causing a wide variety of signs and symptoms): 1 person, 8.33%
Acrodermatitis (skin condition that typically affects children between the ages of 6 months and 12 years): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Raptiva and have Dermatitis - atopic?

- Check whether Dermatitis - atopic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Raptiva:

Raptiva (3,769 reports)

Browse all side effects of Raptiva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis - atopic:

Dermatitis - atopic (2,002 drugs)

Browse all the conditions that are associated with Dermatitis - atopic:

Dermatitis - atopic (1,973 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on efalizumab (the active ingredients of Raptiva) and Raptiva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.